Andreas Halvorsen's hedge fund firm Viking Global has filed a 13G with the SEC regarding their stake in Salix Pharmaceuticals (SLXP). Per the filing, Viking now owns 5% of the company with over 3.19 million shares.
They've increased their holdings by 305,850 shares and the filing was made due to activity on August 8th.
We recently highlighted some other portfolio activity from Viking Global as well.
Per Google Finance, Salix Pharmaceuticals is "a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract."
Friday, August 15, 2014
Viking Global Boosts Salix Pharmaceuticals Stake
blog comments powered by Disqus
